Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 5/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | NOS1 | P29475 | 4/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | APEX1 | P27695 | 1/20 | 0.37 |
| ▸ | NOS3 | P29474 | 1/20 | 0.37 |
| ▸ | NOS2 | P35228 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5021113 | 0.81 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2MAPTL3MBTL1NOS1 | |
| SCHEMBL9353516 | 0.74 | SMN1; SMN2 (0.42) | ALDH1A1SMN1; SMN2MAPTL3MBTL1NOS1 | |
| SCHEMBL31555007 | 0.74 | SMN1; SMN2 (0.49) | ALDH1A1SMN1; SMN2MAPTL3MBTL1NOS1 | |
| SCHEMBL16411604 | 0.74 | SMN1; SMN2 (0.49) | ALDH1A1SMN1; SMN2MAPTL3MBTL1NOS1 | |
| SCHEMBL9355658 | 0.71 | SMN1; SMN2 (0.42) | ALDH1A1SMN1; SMN2MAPTL3MBTL1NOS1 | |
| SCHEMBL15528437 | 0.71 | ALDH1A1 (0.41) | ALDH1A1SMN1; SMN2MAPTL3MBTL1NOS1 | |
| SCHEMBL9278954 | 0.70 | MAPT (0.47) | ALDH1A1SMN1; SMN2MAPTNOS1MEN1 | |
| SCHEMBL27912633 | 0.69 | ALDH1A1 (0.41) | ALDH1A1SMN1; SMN2MAPTL3MBTL1NOS1 | |
| SCHEMBL17275486 | 0.69 | PKM (0.40) | MAPTMEN1KMT2AKDM4ECYP1A2 | |
| SCHEMBL28625430 | 0.69 | PKM (0.40) | MAPTMEN1KMT2AKDM4ECYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10392422-B2 | Macrocyclic broad spectrum antibiotics | RQX PHARMACEUTICALS, INC. (US) | 2019-08-27 | — | — | US | disclosed |
| US-10351595-B2 | — | — | 2019-07-16 | — | — | US | disclosed |
| US-20170088582-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS, INC. (US) | 2017-03-30 | — | — | US | disclosed |
| US-20170088582-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS, INC. (US) | 2017-03-30 | — | — | US | disclosed |
| WO-2015179441-A2 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS, INC. (US) | 2015-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10351595-B2 | — | MRPL21, PRSS1, PEPD | ALDH1A1 2620/4885SMN1; SMN2 1787/4885MAPT 4313/4885 |
| US-10392422-B2 | Macrocyclic broad spectrum antibiotics | MRPL21, PEPD, CTSC | ALDH1A1 2364/4885SMN1; SMN2 1689/4885MAPT 4006/4885 |
| US-20170088582-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | MRPL21, PEPD, CTSC | ALDH1A1 2364/4885SMN1; SMN2 1689/4885MAPT 4006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.